An interventional study of Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions in Cardiac Disease and Cognitive Dysfunction, sponsored by Instituto Nacional de Cardiologia de Laranjeiras. Completed at 2 sites in Brazil. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by Instituto Nacional de Cardiologia de Laranjeiras · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Heart Diseases with a site in Brazil — 11 open to participants now, 12 under way, 3 of them phase 3. Heart Diseases · Brazil.
Among the 48 studies in Heart Diseases with a site in Brazil, this one is the 20th largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2021, is one of 21 with no phase, and was the 32nd registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →11 of the 48 studies in Heart Diseases with a site in Brazil are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in Brazil, United States, Canada and 6 more countries
Ages 6+
Eli Lilly and Company · Sites in Brazil, Argentina, Australia and 35 more countries
Ages 50+
Lexeo Therapeutics · Sites in Brazil, United States, Canada and 5 more countries
Ages 6+
Abbott Medical Devices · Sites in Brazil, France, Germany and 6 more countries
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in Brazil, United States, Argentina and 21 more countries
Ages 18–75
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 16 · Phase 4 5
First in 2004; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 326 is above the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 274 across the 44 interventional studies, 297 across the 4 observational. Of the 29 that completed or were terminated, 13 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 48 have an industry lead sponsor. The 10 most frequent:
Instituto Nacional de Cardiologia de Laranjeiras is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Instituto Nacional de Cardiologia de Laranjeiras has 1 study filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Diseases with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
| NCT06865482Lexeo TherapeuticsClinical Course Of Disease In Participants With FA-CM | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Heart Diseases with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neurological dysfunction continues to be one of the complications of considerable concern in patients undergoing cardiac surgery. It was previously reported in the literature, that cerebral oxygen desaturation during cardiac surgery was associated with an increased incidence of cognitive impairment. This study aims to determine whether continuous monitoring of cerebral oximetry improves the neurocognitive outcome in coronary artery bypass surgery when associated with predetermined intervention protocol to optimize cerebral oxygenation.
Despite all the progress over the last decades regarding the improvement of the perioperative care of patients with heart disease and the development of new surgical techniques, neurological dysfunction continues to be one of the complications of the greatest concern in patients undergoing cardiac surgery with cardiopulmonary bypass. Brain injury can manifest itself through permanent or temporary injury, contributing to the increase in-hospital mortality, in the length of stay in intensive care, in the length of hospital stay, to a higher incidence of motor dysfunction requiring rehabilitation, and consequently, to reduced quality of life.
Even though the causes of brain injury are multifactorial, perioperative cerebral hypoperfusion, tissue hypoxia, and thromboembolic events are among the main factors related to neurological dysfunction.
Several clinical studies have indicated an association between cerebral desaturation and the increase of neurological complications. Cerebral oximetry monitoring using near-infrared spectroscopy (NIRS) is a non-invasive technique used to estimate regional cerebral oxygen saturation (rSO2) and has been associated with diminishing the incidence of neurological complications.
There is no consensus in the literature about its real benefit, mainly due to the absence of well-designed scientific studies that demonstrate that cerebral desaturation associated with intervention measures to improve rSO2, are related to the prevention of neurological dysfunction in adult cardiac surgery.
The study hypothesis evaluates whether continuous monitoring of cerebral oximetry improves the neurocognitive outcome in coronary artery bypass surgery when associated with early interventions to optimize rSO2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The following procedures should be performed sequentially in the event of cerebral desaturation after 30 seconds: 1. The positioning of the head, the presence of facial plethora, and bad position of catheters should be corrected; 2. In case of arterial hypotension, the causal factors should be assessed and treated; 3. In the presence of arterial hypoxemia, the causal factors should be assessed and treated to maintain a PaO2 \> 150 mmHg; 4. In the presence of hypercapnia, adjust the ventilation parameters avoiding hyperventilation; 5. In the presence of anemia, the causal factors should be assessed, and the decision to undergo transfusion should also take into consideration the presence of tissue hypoperfusion; 6. In cases of SvO2 below 70% and signs of hemodynamic instability, optimize fluid replacement and ventricular global contractility; 7. Assess the increase of brain consumption of O2, avoiding the superficial level of anesthesia, hyperthermia, and tremors.
Device: Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions
Patients will be treated according to the attending anesthesiologist, without the monitoring of cerebral oximetry, but to maintain a heart rate between 70 - 100 bpm, lactate levels \<3 mmol/L and urine output\> 0.5mL/Kg/h. In case of arterial hypotension the causal factors should be assessed and treated; in case of SvO2 below 70% and signs of hemodynamic instability, optimize volume replacement and global ventricular contractility through inotropic agents (epinephrine, dobutamine or milrinone); in the presence of anemia (Hb \<6 to 7g/dL during CPB or Hb \<8g/dL in the pre-CPB or post-CPB period), the causal factors should be assessed and the decision to transfuse should also take into account the presence of hypoperfusion tissue (increased lactate, low SvO2, acidosis); in episodes of bradycardia with hemodynamic instability, atropine may be used.
In the intervention group, an alarm threshold below 15% of the baseline rSO2 value will be established. Based on the predetermined algorithm the rSO2 will be maintained at or above 85% of the baseline measurements. If the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed to restore rSO2 to baseline levels.
Preoperative cognitive function
Mini Mental State Examination (MMSE)
Time frame: Pre-surgery (within 10 days before)
Postoperative cognitive dysfunction - delayed cognitive recovery
Mini Mental State Examination (MMSE)
Time frame: Post-surgery (7 days after surgery)
Postoperative cognitive dysfunction - neurocognitive disorder
Mini Mental State Examination (MMSE)
Time frame: Post-surgery (90 days after surgery)
Preoperative cognitive function II
Montreal Cognitive Assessment (MoCA) test
Time frame: Pre-surgery (within 10 days before)
Postoperative cognitive dysfunction - delayed cognitive recovery II
Montreal Cognitive Assessment (MoCA) test
Time frame: Post-surgery (7 days after surgery)
Postoperative cognitive dysfunction - neurocognitive disorder II
Montreal Cognitive Assessment (MoCA) test
Time frame: Post-surgery (90 days after surgery)
Preoperative cognitive function III
The Telephone Interview for Cognitive Status (TICS)
Time frame: Pre-surgery (within 10 days before)
Postoperative cognitive dysfunction - delayed cognitive recovery III
The Telephone Interview for Cognitive Status (TICS)
Time frame: Post-surgery (7 days after surgery)
Postoperative cognitive dysfunction - neurocognitive disorder III
The Telephone Interview for Cognitive Status (TICS)
Time frame: Post-surgery (90 days after surgery)
Incidence of postoperative delirium
Delirium will be assessed postoperatively for seven days or until discharge
Time frame: Delirium assessment CAM-ICU preoperatively (baseline) and postoperatively twice a day during the first seven days or until discharge
Neurological injury type I (stroke)
The incidence of neurological injury type I will be evaluated for 30 days
Time frame: Post-surgery (until 30 days after surgery)
Duration of mechanical ventilation
The duration of mechanical ventilation will be evaluated
Time frame: Post-surgery (until 30 days after surgery)
Length of stay at the intensive care unit (ICU)
The length of stay at the intensive care unit (ICU) will be evaluated
Time frame: Post-surgery (until 30 days after surgery)
Length of stay at the hospital
The length of stay at the hospital will be evaluated
Time frame: Post-surgery (until 30 days after surgery)
Incidence of mortality resulting from all causes
All causes of mortality will be assessed for 30 days
Time frame: Post-surgery (until 30 days after surgery)
Plan to share: No
Ran from May 2021 to primary completion in Aug 2024, 39 months.
Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's 39 months is above that.
Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Nacional de Cardiologia de Laranjeiras